Salix: Colazal, INKP-102 advancing in trials

By E. Janene Geiss

Philadelphia, Nov. 1 - Salix Pharmaceuticals, Ltd. said Tuesday that the company's drug candidates Colazal and INKP-102 are progressing well through trials.

Colazal is proving to be effective in the prevention of acute radiation-induced proctosigmoiditis and other toxicities associated with pelvic radiotherapy, according to a company news release.

The abstract results on Colazal, which were presented at the American College of Gastroenterology's annual scientific meeting, confirm the utility of Colazal as a highly potent anti-inflammatory agent and underscore the importance of the proper colonic delivery of the active ingredient, 5-ASA, to the colon, Bill Forbes, vice president, research and development and chief development officer, said in the release.

"Colazal's prodrug formulation has demonstrated the ability to deliver 99% of the 5-ASA dose to the colon," Forbes said.

Also presented at the conference were seven abstracts based on results of two randomized, multicenter, investigator-blinded trials in about 1,000 patients comparing various dosing regimens of the company's next-generation purgative product, INKP-102 to Visicol tablets in adults undergoing colonoscopy.

The findings of these studies, Forbes said in the release, show that INKP-102 may soon provide gastroenterologists and their patients a next-generation colonic cleaning product characterized by excellent efficacy, dosing and tolerability profile.

Salix Pharmaceuticals is a Morrisville, N.C., pharmaceutical company focused on products for gastroenterologists.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.